Hybrid Closed-Loop System in LADA Patients: A Randomized Trial

NCT06941675 · tracked via the Priya Life Science China tracker

Sponsor

Shanxi Bethune Hospital

Phase

Not applicable

Started

2025-04-01

Last updated

2025-04-24

Condition(s) studied

Latent Autoimmune Diabetes in Adults (LADA)

Investigational drug(s) / intervention(s)

Hybrid Closed-Loop Artificial Pancreas System

Hybrid Closed-Loop Artificial Pancreas System: Hybrid Closed-Loop Artificial Pancreas System Group: Uses an open-source system with Novo Nordisk ultra-rapid-acting insulin (approval: J20050097, 3 mL: 300 U). Daily insulin dose calculated at 0.3-0.6 U/(kg\*d) based on weight; system auto-adjusts basal rate. Physicians prescribe bolus doses, entered by nurses via AAPS software. Glucose correction uses CGM + 4 daily capillary tests (fasting, 2h post-meal). AAPS features hypoglycemia prediction suspend (pauses basal if glucose ≤4.4 mmol/L, resumes upon recovery) and alarms (\<3.9 mmol/L, ensures nighttime alert).

Study summary

Based on the difficulties in blood glucose control among the Latent Autoimmune Diabetes in Adults (LADA) population and the deficiencies of previous studies, this research aims to conduct a clinical comparative study. The short-term blood glucose control effects of the closed-loop system and the combination of a conventional insulin pump and Continuous Glucose Monitoring (CGM) in hospitalized LADA patients will be evaluated to explore the clinical application value of these methods in LADA patients. Moreover, this study aims to provide a more precise and personalized blood glucose management plan for LADA patients. As a slowly progressive subtype of autoimmune type 1 diabetes mellitus (T1DM), LADA patients have significant differences in pathological characteristics, clinical needs, and treatment effects compared with classical T1DM patients. However, they also face huge challenges in blood glucose management. This study will focus on LADA patients for the first time, especially the group of hospitalized patients, to fill the gap in this field. Meanwhile, by introducing the cutting-edge closed-loop system technology, it will provide new ideas and solutions for the clinical blood glucose management of LADA patients. Through a comparative analysis of the short-term blood glucose control effects of the closed-loop system and the combination of a conventional insulin pump and CGM, this study aims to provide more precise and personalized treatment strategies for LADA patients and promote the further development of diabetes treatment technologies.

Eligibility

Sex

ALL

Min age

18 Years

Max age

70 Years

Healthy volunteers

Inclusion Criteria: 1. Age between 18 and 70 years old. 2. Meet the diagnostic criteria for LADA in the "Chinese Expert Consensus on the Diagnosis and Treatment of Latent Autoimmune Diabetes in Adults (2021 Edition)": * The onset age of diabetes is ≥ 18 years old. * Positive for islet autoantibodies or islet autoimmunity T cells. * Do not rely on insulin therapy for at least 6 months after the diagnosis of diabetes. 3. Patients are able to correctly use insulin pumps and CGM devices and have a certain learning ability and operational ability. 4. Baseline HbA1c \> 7.0% or HbA1c \> 6.0% combined with hypoglycemia. 5. Patients agree to participate in the study and sign the informed consent form. Exclusion Criteria: 1. The patient has been clearly diagnosed with type 2 diabetes or special types of diabetes. 2. The patient has experienced acute diabetic complications within the past 1 month, such as diabetic ketoacidosis, hyperglycemic hyperosmolar coma, etc. 3. The patient has severe symptoms of hypoglycemia intolerance. 4. The patient has skin diseases such as rashes and prurigo, or abnormal coagulation function. 5. The patient has diseases related to impaired glucose metabolism, such as uncontrolled hyperthyroidism, hypothyroidism, Cushing's syndrome, etc. 6. The patient has comorbid severe liver, kidney, gastrointestinal, hematological, brain, circulatory system diseases, etc. 7. The patient has other severe chronic diseases (such as malignant tumors, end-stage organ failure, etc.). 8. The patient has impaired consciousness or mental illness, lacks self-control, and cannot express clearly. 9. Lactating women, pregnant women, or women who plan to become pregnant during the trial period. 10. The patient is currently using or has used glucocorticoids or other drugs that interfere with glucose metabolism within 1 month before screening. 11. The patient is allergic to the drugs involved in the clinical diagnosis and treatment plan. 12. The patient is currently using other closed-loop systems. 13. People who are not suitable for conventional insulin pump treatment and those with contraindications. 14. The patient is known or suspected to have an insulin-allergic constitution and is allergic to adhesive tape, insulin pumps, or CGM devices. Other situations where the researcher deems the patient unfit to participate in the clinical trial.

Primary outcome measure(s)

Time required to achieve 70% TIR — 2 years
Time in Range (TIR) refers to the percentage of time that blood glucose levels are within the target range of 3.9 to 10.0 mmol/L. The calculation formula is: TIR = (Time within the target range / Total time) × 100%
TIR achievement rate after 5 days of treatment — 5 days
Time in Range (TIR) refers to the percentage of time that blood glucose levels are within the target range of 3.9 to 10.0 mmol/L. The calculation formula is: TIR = (Time within the target range / Total time) × 100%

Trial sites (1)

Facility	City	Region	Status
Shanxi Bethune Hospital	Taiyuan	Shanxi	Recruiting

More Shanxi Bethune Hospital trials in China

Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study Recruiting

CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma Recruiting

Integrated TCM - Western Medicine Strategy for Long - Distance Diabetes Management Recruiting

Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study Recruiting

Intraosseous Infusion in Hematologic Critical Patients Recruiting

Other trials for the same condition

Effects of Cofrogliptin on Beta-Cell Function in LADA Patients Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06941675 on ClinicalTrials.gov ↗ ← All trials in China